RecruitingNon-small Cell Lung Cancer

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Eligible age

18–95 yrs

Accepts

All genders

Locations

17 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combination with Durvalumab or Rilvegostomig and single agent platinum chemotherapy in participants with resectable, early-stage non-small cell lung cancer.

Sponsor: AstraZeneca

You may qualify if…

✓ Newly diagnosed NSCLC patients with resectable disease (Stage IIA to Stage IIIB).
✓ WHO or Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
✓ Adequate organ and bone marrow function.
✓ Provision of tumour samples (newly acquired or archival tumour tissue \[≤ 6 months old\]) to confirm Programmed death-ligand 1 (PD-L1) status, epidermal growth factor receptor (EGFR), or anaplastic lymphoma kinase (ALK) status.
✓ Adequate pulmonary function.

You may not qualify if…

✕ Participants with sensitising EGFR mutations or ALK translocations.
✕ Participants with baseline PD-L1 expression status \<1% (Arms 6 and 7 only).
✕ Active or prior documented autoimmune or inflammatory disorders.
✕ Uncontrolled intercurrent illness, uncontrolled hypertension, unstable angina pectoris, uncontrolled cardiac arrhythmia, active bleeding diseases, serious chronic gastrointestinal conditions associated with diarrhoea, or psychiatric illness/social situations that would limit compliance with study requirement.
✕ History of another primary malignancy.
✕ Participants with small-cell lung cancer or mixed small-cell lung cancer.
✕ History of active primary immunodeficiency.
✕ History of non-infectious interstitial lung disease (ILD) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.